The purpose of the trial is to evaluate the safety and effectiveness of this drug combination. The study begins with a short safety‑checking phase and, if tolerated, moves to a larger phase that looks at how well the treatment shrinks or controls the tumor. Participants receive the infusions every few weeks and undergo regular imaging scans to see changes in tumor size; the study continues until the disease progresses, the participant chooses to stop, or the study ends.

The main goal of the trial is to learn how safe the medicine is and how well patients can tolerate increasing doses. Participants will receive the drug in a series of treatment cycles that last about four weeks each, with the amount of medicine gradually increased in early groups to find the highest dose that can be given without unacceptable side effects.

During the study, patients will have regular check‑ups, blood tests, and scans to watch for any side effects and to see how the cancer responds. Any problems that arise will be recorded and managed by the medical team, and the study will continue until the predetermined number of treatment cycles is completed or if a participant chooses to stop early.

The study has more than one part. In the first part, small groups of people receive the drug combinations so that researchers can watch for side effects and choose a dose that can be used more widely. In the later part, more people receive the combinations to learn more about how the treatment works in the different cancer groups and to compare dose options in some groups. Because this is an open-label trial, everyone knows which treatment is being given.

During the trial, the treatment is given over time, and participants are followed closely while they are receiving it and for a period afterward. Doctors check for side effects, how well the cancer seems to respond, and how the body handles the drugs. The study includes people with several cancer types, and the treatment plan may differ depending on the cancer group and the study part.

The purpose of the study is to compare the effectiveness of a new medicine with that of standard chemotherapy. The investigational drug being tested is Sofetabart Mipitecan (LY4170156). For participants with platinum-resistant disease, the new drug may be given alone and compared with the doctor’s choice of chemotherapy drugs such as carboplatin, paclitaxel, gemcitabine, topotecan or doxorubicin, or with Mirvetuximab Soravtansine. For those with platinum-sensitive disease, the new drug is combined with bevacizumab and compared with a standard platinum‑based two‑drug chemotherapy regimen plus bevacizumab.

Participants receive the study medicines through an IV infusion every few weeks and attend regular clinic visits where doctors perform physical examinations and imaging scans to check how the cancer is responding. Treatment continues until the cancer grows, side effects become unacceptable, or the study period ends, which may be several months for each participant.

The treatment involves the intravenous administration of SGN-ALPV, meaning the medicine is delivered directly into a vein through a needle or tube. Participants in the study will receive the drug in different amounts to help researchers determine the highest dose that can be given safely without causing too many side effects. During the study, medical professionals will monitor how the body reacts to the medication and how much of the drug remains in the bloodstream over time.

The investigation uses a specialized technique known as PET, which is a type of scan used to visualize how certain substances work inside the body. During the process, the substance [68Ga]BED003 is administered through an intravenous injection, meaning it is delivered directly into a vein. This substance is designed to target a specific protein found in certain tumor environments to help create clearer images. The scans are often combined with a computed tomography, which uses X-rays to create detailed pictures of the body’s internal structures.

Participants in the study will undergo imaging to see how well the new substance can identify cancer cells within the peritoneum, which is the thin layer of tissue that lines the inner wall of the abdomen and covers most of the organs. The study will monitor how the imaging agent behaves over time and check for any side effects. The goal is to determine if this new method can provide more accurate information about the presence and location of these cancers compared to standard medical practices.

Participants in the study will receive medications through an intravenous infusion, which is a method of delivering medicine directly into a vein. The study involves comparing different combinations of drugs to see how they affect progression-free survival, a term used to describe the length of time during and after treatment that a person lives with the disease without it getting worse. Other factors being observed include overall survival and the quality of life, which tracks how well a person can perform daily activities and their general well-being during the study.

The purpose of this study is to find out if romiplostim can help maintain platelet counts high enough to allow patients to receive their full chemotherapy doses on time without delays or reductions. The study will compare romiplostim with placebo to measure its effectiveness. Participants entering the study must have a platelet count at or below a certain level and must have at least three more cycles of chemotherapy planned. The chemotherapy cycles are given every 21 or 28 days depending on the specific treatment plan.

During the study, participants will receive either romiplostim or placebo as an injection under the skin while continuing their regular chemotherapy treatment. The study medication will be given for a treatment period lasting up to 12 weeks. Doctors will monitor platelet counts, track whether chemotherapy doses need to be changed due to low platelets, and watch for any bleeding problems or other side effects. Participants will continue to be followed for safety monitoring for up to 36 months to check for any long-term effects.

Patients in this study will receive zanidatamab on its own, without combining it with other cancer treatments. The medicine will be given regularly over a treatment period that can last up to 60 weeks. The doctors will check how the tumors respond to the treatment by doing regular scans and tests. Some patients in the study may have breast cancer or cancers of the stomach and food pipe area, and they may have received a specific type of HER2-targeted therapy before, which is a treatment that works against the HER2 protein. For other types of solid tumors, patients should not have had this type of treatment before.

During the study, doctors will monitor patients carefully to see if the treatment is working and to watch for any side effects. This includes checking heart function, blood tests to see how the liver and kidneys are working, and measuring the size of the tumors. Patients will also be asked about symptoms they experience using questionnaires. The study will look at how many patients see their tumors shrink, how long the treatment keeps working, and how long patients live. Blood samples will be taken to measure the amount of medicine in the body and to check if the body makes any reaction against the medicine.

The new medication, identified by the code name INCB123667, is given as a tablet taken by mouth each day. Participants may receive one of several standard chemotherapy options chosen by their doctor, including paclitaxel, topotecan, gemcitabine, or doxorubicin, all of which are administered through an intravenous (IV) infusion, meaning the drug is delivered directly into a vein.

After enrollment, participants are assigned to receive either the study pill or one of the IV chemotherapy drugs and are followed with regular clinic visits, imaging scans to check tumor size, blood tests, and quality‑of‑life questionnaires for several months. The trial will record how long patients live without the disease getting worse, known as progression‑free survival, and how long they live overall, referred to as overall survival, to evaluate the relative benefit of the treatments.

The purpose of the study is to find out if this treatment is safe and to determine the best dose that patients can tolerate. The study will also look at whether the treatment helps to control or shrink the tumors. Patients in this study must have tumors that show the presence of the CLDN6 protein and must have cancer that has spread or cannot be removed by surgery. The treatment is given through an infusion into a vein. During the study, doctors will closely monitor patients for any side effects and will measure how the tumors respond to the treatment using imaging scans or blood tests that measure certain markers in the blood.

The study will follow patients for several years to understand the long-term effects of the treatment and how well it works over time. Doctors will collect blood samples to measure changes in the immune system and to see how long the modified immune cells stay in the body. The study will test different doses of the cell therapy and the vaccine to find the most appropriate amount to use in future studies. Some patients will receive treatment made using a manual process while others will receive treatment made using an automated process to compare whether both methods work similarly.

The purpose of this study is to assess the safety of this treatment combination by monitoring for serious side effects and determining the best dose to use in future studies. The trial is designed as a first-line treatment approach given before surgery, meaning it is intended to shrink the tumors before they are removed. Patients will first have tumor tissue collected so that the TIL cells can be prepared. After the cells are ready, they will be given back to the patient through infusion, followed by treatment with low-dose aldesleukin to help the immune cells work better against the cancer.

During the study, doctors will carefully monitor patients for any side effects related to the treatment, paying special attention to serious reactions. The study will also examine how the treatment affects different types of immune cells in the body and whether it helps control the cancer. This research aims to determine whether this immune-based treatment approach is safe enough to be tested more widely in patients with advanced ovarian cancer who are not initially suitable for surgery.

The purpose of this study is to see how well these medicine combinations work at shrinking or stopping the growth of the cancer, and to check how safe they are for people to take. The study will also look at which dose levels work best when the medicines are used together compared to using tuvusertib alone. The study is divided into two parts. In the first part, called Part A, people will receive either tuvusertib combined with niraparib or tuvusertib combined with lartesertib. The results from Part A will help decide which combination works better and should be studied further. In the second part, called Part B, people will receive the best combination chosen from Part A at two different dose levels, or they will receive tuvusertib by itself. This will help compare how well the combination works compared to tuvusertib alone and will help determine the best dose to use in future treatments.

During the study, people will take their assigned medicines and will have regular check-ups to see how the cancer is responding to treatment and to watch for any side effects. These check-ups will include scans to measure the size of the cancer and blood tests to check overall health. The treatment can continue for up to 42 months as long as the cancer does not get worse and the medicine is not causing serious problems. The study will measure how many people have their cancer shrink, how long the cancer stays under control, how long people live without the cancer getting worse, and how long people live overall. The study will also carefully track any unwanted effects or health problems that occur during treatment.

The purpose of this study is to check whether this treatment method is safe and practical for older and more fragile women with advanced ovarian cancer who may not be suitable for a similar treatment that uses heat. The study will look at how the treatment affects the body, including any side effects or complications that may occur during or after surgery. It will also measure how the drug moves through the body and how it affects both healthy tissue and cancer tissue in the abdominal area. Additionally, the study will examine how this treatment affects inflammation and blood flow in the tissues.

Women participating in this study will first receive chemotherapy before surgery to shrink the cancer. Then, during surgery to remove the cancer, they will receive carboplatin directly into the abdominal cavity. After surgery, they will be monitored for any complications and side effects. The study will track how long patients stay in the hospital, whether they need additional surgeries, and how soon they can start additional chemotherapy after surgery. The study will also look at quality of life through questionnaires and will measure various biological markers in both tissue samples and blood to understand how the treatment works. The entire study is expected to continue until 2027.

The study is divided into different parts called substudies. In one substudy, people will have a specific type of ovarian cancer that has certain characteristics, including being what doctors call high-grade serous cancer, which is a particular form of the disease. Some people in this substudy will have cancer that does not have certain genetic changes. In another substudy, people will have ovarian cancer that has come back after previous treatment with platinum-based chemotherapy, and their cancer must have returned more than six months after finishing that treatment. People in the study will receive different combinations of the medicines, and doctors will check how their cancer responds to treatment and watch for any side effects.

During the study, doctors will measure several things to understand how well the treatments work and how safe they are. They will count how many people have side effects of any severity, including serious ones, and how many people need to stop treatment because of side effects. They will pay special attention to eye problems, nerve problems, and lung problems that might occur. Doctors will also check whether the cancer shrinks or stops growing by using scans and blood tests. They will measure how long people live without their cancer getting worse and how long the cancer responds to treatment when it does shrink.

The purpose of the study is to see how well INCB123667 works in treating this type of cancer when the disease no longer responds well to platinum-based treatments. Platinum-resistant disease means that the cancer has either grown or come back within six months after the last platinum treatment, or has continued to grow during platinum treatment. The study will look at whether the treatment can shrink the tumors or stop them from growing. Participants in this study will have already received between one and four previous treatment plans for their cancer, and will have a tumor sample tested to confirm that cyclin E1 is overexpressed and to check the level of another protein called FRα.

During the study, participants will take INCB123667 tablets for up to 24 months. Before starting treatment, a tissue sample from the tumor will be collected. The study doctors will regularly check how the cancer is responding to treatment using imaging scans and will monitor for any side effects through physical examinations, blood tests, and heart monitoring. The study will track how long any tumor shrinkage lasts, how long participants live without their disease getting worse, and overall survival. Safety will be closely monitored throughout the study by checking for unwanted effects and whether any dose changes are needed.

The purpose of this research is to test how safe bemarituzumab is and how well it works in treating different types of solid tumors. The study is divided into two parts. In the first part, doctors will closely monitor how patients respond to the medication and any side effects that may occur. In the second part, they will evaluate how effective the medication is at fighting the cancer.

During the study, patients will receive bemarituzumab through regular infusions. The doctors will track the progress of the treatment using different medical tests and imaging scans such as computed tomography (CT) or magnetic resonance imaging (MRI). They will monitor how the tumors respond to the treatment and keep track of any changes in the patient’s health throughout the study period.

The study will test MK-5684 alongside several other medications that may be used as standard treatments, including tamoxifen, exemestane, letrozole, fulvestrant, megestrol, and medroxyprogesterone. Some participants may also receive medications to manage side effects, such as dexamethasone, hydrocortisone, and fludrocortisone.

During the study, participants will receive either MK-5684 or standard treatment medications. The study will track how long participants live without their cancer getting worse, their overall survival time, and how well they respond to treatment. Doctors will monitor participants for any side effects throughout the treatment period, which may last up to 60 months.

The main goal of this research is to determine if Saruparib is safe to use and to understand how well it works in treating advanced ovarian cancer. The study will look at how patients’ bodies respond to the medication and what side effects may occur. During the study, patients will receive regular medical check-ups, including blood tests and imaging scans to monitor their health and how the cancer responds to treatment.

This is a master protocol study, which means it consists of several smaller studies testing different aspects of the treatment. Throughout the study, doctors will monitor various health indicators and collect information about how the medication affects the cancer. They will also measure the amount of medication in the blood and track changes in a substance called CA125, which can indicate how well the treatment is working.

The treatment involves receiving TORL-1-23 through an intravenous infusion (given directly into a vein). During the study, participants may also receive pegfilgrastim, a supportive medication that helps the body produce white blood cells after treatment. The study treatment may continue for up to 24 months, depending on how well participants respond to the therapy.

The study medication TORL-1-23 is designed to specifically target cancer cells that have the CLDN6 protein on their surface. It works by delivering a cancer-fighting substance directly to these cells while aiming to minimize effects on healthy cells. This targeted approach represents a new way of treating these types of cancer that no longer respond to standard platinum-based treatments.

The purpose of this research is to determine if using these two medications together is more effective than using bevacizumab by itself in treating ovarian cancer. The study specifically looks at patients who have recently been diagnosed with advanced stages of the disease. Both medications are types of targeted therapy – bevacizumab works by affecting blood vessel growth in tumors, while trastuzumab deruxtecan is an antibody-drug conjugate that specifically targets cancer cells expressing the HER2 protein.

During the study, patients will receive treatment for up to 24 months. The medications will be given through regular infusions at specified intervals. Throughout the treatment period, doctors will monitor patients’ responses to the therapy and track any changes in their condition. This research is particularly focused on patients whose cancer shows specific levels of a protein called HER2 on their tumor cells.

The study will assess COM701 as a maintenance treatment, which means it will be given after the main cancer treatment to help keep the cancer from returning. Some participants will receive COM701 while others will receive placebo. The research will measure how long patients remain without disease progression while receiving the maintenance therapy.

The safety of COM701 will be carefully monitored throughout the study by tracking side effects, laboratory test results, vital signs, and heart activity. The trial will also track how long it takes before patients need to start a new cancer treatment.

The purpose of the study is to determine how accurately the sentinel lymph node technique can predict whether cancer has spread to lymph nodes. This will be compared with the current standard approach of pelvic/aortic lymphadenectomy (surgical removal of lymph nodes in the pelvic and aortic regions). During the study, participants will undergo a surgical procedure where a tracer substance is injected near the tumor to identify the sentinel lymph nodes, which are then removed and examined for cancer cells.

This research may help determine if the sentinel lymph node technique can provide reliable information about cancer spread while potentially allowing for less extensive surgery than complete lymphadenectomy. The technique could potentially reduce surgical complications while maintaining accurate cancer staging information.

The purpose of this study is to determine the safety, appropriate dosage, and preliminary effectiveness of THEO-260 for treating these types of ovarian cancer. The study is divided into two parts: the first part focuses on finding a safe dose and evaluating side effects, while the second part examines whether the treatment is effective against the cancer at the recommended dose.

During the trial, participants will receive THEO-260 and undergo various assessments including blood tests, imaging scans (CT or MRI), and quality of life questionnaires. The researchers will monitor for side effects, including potential immune-related adverse events (side effects related to the immune system) and cytokine release syndrome (a condition that can cause fever and other symptoms when certain treatments activate the immune system).

Participants in the study will receive either Rina-S or one of several other treatments, which may include topotecan, glatiramer acetate, paclitaxel, doxorubicin hydrochloride, or gemcitabine hydrochloride. These treatments are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. The study will last for up to 36 months, during which time the participants’ health and response to the treatment will be closely monitored.

The purpose of the study is to determine how well Rina-S works compared to the other treatments in terms of delaying the progression of the cancer. The study will also look at other important factors, such as overall survival, the response of the cancer to the treatment, and the quality of life of the participants. This information will help doctors understand the best ways to treat platinum-resistant ovarian cancer in the future.

The purpose of this study is to evaluate how effective this combination of medications is in treating the specified types of cancer. Participants in the study will receive these medications and will be monitored over time to assess their response to the treatment. The study will track the progression of the disease and any changes in the participants’ health. The trial aims to gather information on how well the treatment works and any side effects that may occur.

Throughout the study, participants will undergo regular check-ups and assessments to monitor their health and the impact of the treatment. The study is designed to provide valuable insights into the potential benefits and risks of using relacorilant in combination with nab-paclitaxel and bevacizumab for treating these advanced cancers. This research could contribute to developing more effective treatment options for patients with these types of cancer in the future.

The purpose of the study is to assess how well Raludotatug Deruxtecan works in treating these cancers and to monitor any side effects. Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will follow participants over a period to observe the treatment’s impact on their cancer and overall health.

Throughout the trial, researchers will focus on understanding how the treatment affects the size and growth of the tumors, as well as any changes in the participants’ health. The study aims to provide valuable information on the potential benefits and risks of using Raludotatug Deruxtecan for these types of cancers, contributing to future treatment options for patients with advanced or metastatic solid tumors.

The purpose of the study is to learn more about how well the treatment works and how safe it is for participants. The study will involve taking the medication by mouth for a period of up to 36 months. Participants will be monitored regularly to see how their tumors respond to the treatment and to check for any side effects. The study will also look at how long the treatment keeps the disease under control and how it affects the overall health and quality of life of the participants.

Participants in the study will have regular check-ups and tests to track their progress. These tests will help researchers understand the effectiveness of the treatment and any potential risks. The study aims to provide valuable information that could lead to better treatment options for people with these types of tumors in the future.

Participants in the study will take Olaparib in the form of film-coated tablets, which are taken by mouth. The study will follow a single group of patients who have been newly diagnosed with these types of cancer and have responded well to their first round of chemotherapy. The study will last for a period of up to 24 months, during which the patients will be monitored to see how long they remain free from cancer progression, which is when the cancer does not get worse.

The study will also look at various factors that might help predict how well patients will do with this treatment. These factors include certain characteristics of the patients and their tumors. The goal is to identify which patients might have a better outcome in terms of overall survival and to understand the safety and side effects of the treatment. This information will help doctors make better decisions about using Olaparib for these types of cancer in the future.

After the initial chemotherapy, patients will be divided into two groups. One group will receive a medication called niraparib alone, while the other group will receive niraparib combined with bevacizumab. Niraparib is taken as a capsule by mouth, while bevacizumab is given through an intravenous infusion. The purpose of this study is to determine if adding bevacizumab to niraparib treatment leads to better results than using niraparib alone.

The study will monitor how long patients remain without their cancer getting worse. Patients will receive regular medical examinations and tests throughout the study period. The treatment may continue for up to 36 months, depending on how well patients respond to the therapy and whether they experience any side effects.

The purpose of the study is to evaluate the safety and effectiveness of PF-07104091 in patients with advanced or metastatic forms of these cancers. The study will be conducted in phases, starting with determining the appropriate dosage of PF-07104091 when used alone. Subsequent phases will assess the safety and potential benefits of combining PF-07104091 with other cancer treatments. Patients will receive either the new treatment or a placebo, and their health will be monitored to understand how the treatment affects their cancer and overall well-being.

Participants in the study will take the medication orally, in the form of capsules or tablets, or receive it through an injection, depending on the specific treatment plan. The study aims to gather information on how the body processes the medication and its impact on tumor growth. This research is crucial for developing new treatment options for patients with these challenging cancer types.

The purpose of the study is to see if this new treatment can improve the immune response in patients with ovarian cancer who are also receiving chemotherapy. The study will involve patients receiving injections of the treatment, which is administered directly into the lymph nodes, a process known as intranodal injection. The study aims to observe how the immune system reacts to this treatment over time.

Participants in the study will receive the treatment alongside their regular chemotherapy. The study will monitor the immune response to see if the treatment helps the body to better target and attack cancer cells. This research is part of an effort to find more effective treatments for ovarian cancer and improve outcomes for patients with this disease.

Participants in the study will receive the treatment as a solution for infusion, which means it will be given through a vein. The study will observe how the treatment affects the cancer and monitor any side effects. The trial will include regular check-ups and assessments to track the progress of the treatment. The study aims to understand how well the treatment works in shrinking the tumors and how safe it is for the patients.

The study will continue for several years, with the goal of gathering enough information to determine the treatment’s effectiveness and safety. This research is important for developing new ways to treat these challenging cancers and could potentially lead to new treatment options for patients in the future.

The purpose of the study is to see if this combination of treatments is effective in patients whose ovarian cancer has come back after previous treatment. Participants in the study will receive these medications through an intravenous infusion, which means the drugs are given directly into a vein. The study will take place over several months, with regular visits to monitor the effects of the treatment and to check on the participants’ health.

Throughout the study, doctors will assess how well the cancer responds to the treatment and monitor any side effects. The goal is to determine if this combination can help manage the cancer in patients who have already been treated with pegylated liposomal doxorubicin and have experienced a return of their cancer. This research could provide valuable information for future treatment options for recurrent ovarian cancer.

Participants in the study will receive either the combination of relacorilant and nab-paclitaxel or nab-paclitaxel by itself. The treatment will be given over a period of 28 days, and the study will monitor how the cancer responds to the treatment. The study aims to see if the combination treatment can help control the cancer better than nab-paclitaxel alone. The study will also look at how long patients live without the cancer getting worse and other measures of how well the treatment works.

This trial is important for understanding if adding relacorilant to nab-paclitaxel can provide a new option for patients with this challenging type of cancer. The study will help determine if the combination treatment can improve outcomes for patients compared to the standard treatment with nab-paclitaxel alone. Participants will be closely monitored throughout the study to ensure their safety and to gather important information about the treatment’s effects.

The medication being tested, fadraciclib, is taken by mouth in tablet form. It belongs to a group of drugs called CDK2/9 inhibitors, which work by blocking certain proteins that help cancer cells grow. The study aims to find the best dose of the medication and determine how well it works in treating these different types of cancer.

During the study, participants take the medication either once or twice daily in 28-day cycles. The treatment continues as long as it is helping and the side effects are manageable. Throughout the study, doctors monitor the participants’ health and how their cancer responds to the treatment. This includes regular check-ups and various medical tests to ensure safety and track the effectiveness of the medication.

The study will be conducted in two phases. In the first phase, different doses of TUB-040 will be tested to determine the safest and most effective dose. This phase will help identify any side effects and how the body processes the medication. In the second phase, the focus will be on optimizing the dose and further assessing the safety and preliminary effectiveness of TUB-040 in treating the cancers.

Participants in the study will receive the medication through an intravenous infusion, and their health will be closely monitored throughout the trial. The study aims to gather important information that could lead to new treatment options for patients with these challenging types of cancer. Some participants may receive a placebo as part of the study design. The trial is expected to continue until early 2027, with recruitment starting in mid-2024.

The purpose of this study is to continue providing treatment to patients who have completed a previous cancer study with Olaparib and are still benefiting from it. The study aims to ensure the safety and tolerability of the ongoing treatment. Patients will continue to receive Olaparib if they are judged by their doctor to be benefiting from the treatment. The study will monitor the patients’ health and any side effects that may occur during the treatment period.

Participants in this study will take Olaparib tablets orally, with the treatment period lasting up to 123 days. The study will keep track of any serious side effects or important medical events that happen up to 30 days after the last dose of the study drug. This trial is designed to help patients who are already experiencing positive effects from Olaparib to continue their treatment safely.

The purpose of the study is to evaluate how well the combination of nemvaleukin alfa and pembrolizumab works compared to chemotherapy in improving the survival of patients with this type of cancer. Participants in the study will receive either the new drug combination or chemotherapy, which may include drugs like topotecan hydrochloride, gemcitabine hydrochloride, paclitaxel, or doxorubicin hydrochloride. The treatment will be given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein.

Throughout the study, participants will have regular visits to monitor their health and the effects of the treatment. The study aims to gather information on overall survival, how long patients live without the cancer getting worse, and the response of the cancer to the treatment. Safety will also be closely monitored by checking for any side effects or changes in health. The study is expected to continue until 2027, providing valuable insights into the effectiveness of this new treatment approach for patients with platinum-resistant ovarian cancer.

The purpose of this research is to determine if using 5-ALA during surgery can help doctors find cancer tissue that might not be visible under normal lighting conditions or through physical examination. The medication is given as a single oral dose of up to 20 milligrams per kilogram of body weight before the surgery.

During the operation, surgeons will examine the surgical area using both normal and special lighting conditions to identify areas of cancer. They will document any additional cancer tissue found with the help of 5-ALA that would not have been detected otherwise. Tissue samples will be taken to confirm the presence of cancer cells. The study will also monitor patients for any side effects that may occur from using this medication.